Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure a prespecified analysis of the SELECT trial /
Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysi...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2024
|
| Sorozat: | LANCET
404 No. 10454 |
| Tárgyszavak: | |
| doi: | 10.1016/S0140-6736(24)01498-3 |
| mtmt: | 35243091 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/34597 |